Rizatriptan Ineffective for Vestibular Migraine Treatment, reveals study
Researchers have discovered in a new study that rizatriptan was ineffective at relieving vestibular migraine attacks within 1 hour and showed only limited symptom improvement at 24 hours. These results do not support the use of rizatriptan for treatment of vestibular migraines. The study was published in JAMA Network by Jeffrey P. and colleagues.
This double-blind, placebo-controlled randomized clinical trial was conducted in two tertiary neurotologic centers. 222 patients (mean age 42.3 years; 70.7% female) were originally enrolled. After prospective observation to establish diagnosis and illness activity over a period, 134 patients (60.4%) with active disease were randomized in a 2:1 ratio to receive either rizatriptan 10 mg or placebo. Each patient was asked to treat up to three discrete attacks of vestibular migraine.
The major results were whether rizatriptan was able to decrease vertigo and unsteadiness/dizziness from moderate or severe to absent or mild at 1 hour after taking medication. Secondary outcomes were total resolution of the symptoms, decrease in headache and related symptoms, rescue medication use, 24-hour symptom status, treatment satisfaction, and quality of life at 48 hours.
Key Findings
The last efficacy analysis comprised 240 attacks with vestibular symptoms rated moderate or severe at treatment.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.